enVVeno Medical Corporation
NVNOHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeenVVeno Medical Corporation enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the. The company carries a $4.6M market cap, placing it firmly in the micro-cap category. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency.
Market Cap
$4.6M
Beta
1.29
P/E (TTM)
—
P/E (Fwd)
-1.07
EPS (TTM)
$-24.99
EPS (Fwd)
$-6.22
ROE
-58.5%
ROA
-36.7%
Cash
$21.5M
Total Debt
$505,000
Free CF
-$9.6M
52W Change
-73.6%
Annual Financials
Cash vs Debt
Where NVNO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NVNO finished 26.06% below its 150-day moving average ($10.40) and 27.04% below its 200-day moving average ($10.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVNO overbought or oversold?
At the October 20, 2026 close, NVNO's RSI(14) was 40.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
enVVeno Medical Corporation holds $21.5M in cash against $505K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$9.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -58.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for enVVeno Medical Corporation and its sector.